RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference ...

After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), ...

Citius Oncology inks distribution services agreement with Cardinal Health: Cranford, New Jersey Wednesday, June 11, 2025, 11:00 Hrs [IST] Citius Oncology, Inc. (Citius Oncology), ...

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) shares are trading higher Monday after the company announced it entered into a ...

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), has entered into a distribution services agreement with Cardinal Health (CAH).

Citius Pharmaceuticals Inc (NASDAQ: CTXR ), the parent company of Citius Oncology, also saw its shares climb by 6.7%. Meanwhile, Cardinal Health’s stock remained flat after the news.

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc.

Fintel reports that on May 23, 2025, Maxim Group downgraded their outlook for Citius Oncology (NasdaqCM:CTOR) from Buy to Hold. Analyst Price Forecast Suggests 248.44% Upside As of May 7 ...